Peptide Receptor Radionuclide Therapy, PRRT: Updates and Locations
Since we shared the news of the FDA’s January 26, 2018 approval of peptide receptor radionuclide therapy, PRRT, with Lutathera (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including…READ MORE
Live Online Carcinoid Syndrome Program for Patients and Caregivers
Patient & Caregiver Education on Carcinoid Syndrome: Talking to Your Doctor About Symptoms, Diet, and Treatment
Last Spring, we were pleased to create an interactive resource for people living with Carcinoid Syndrome with our partner CancerCoachLive – we’ve teamed…READ MORE
Laugh and Learn with Comedian Steve Mazan
Come and laugh with Steve Mazan, stand-up comedian, inspirational speaker, and 13-year NET cancer survivor. “CS Happens” is a Laugh and Learn special evening for the NET community, and is complementary courtesy of Lexicon Pharmaceuticals. This…READ MORE
Endocrinology Society Recognizes Neuroendocrine Cancer Physician and Researcher for Excellence at 2018 Annual Meeting
When Amit Tirosh, MD came to the United States in 2015 to be a senior endocrinologist at the National Institutes of Health (NIH), he began a journey that will lead full circle when he returns to Israel this summer to establish and lead a new neuroendocrine…READ MORE
June Luncheon with the Experts in New York City for the Neuroendocrine Tumor Community
Join neuroendocrine tumor (NET) patients in New York City on Sunday, June 10, 2018 for a unique opportunity to have lunch with two medical experts. Share your experiences with others who have similar concerns and hear from physicians on issues ranging…READ MORE
PRRT – FDA Approves Lutathera®, What’s Next?
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is
Zebra Tales: Carcinoid NETs Health Storylines Launches New Feature
Carcinoid NETs Health Storylines presents Zebra Tales! This brand new feature enables you to learn and share more about the experiences of others within the neuroendocrine tumor (NET) community.
Our first inspiring story is from Stacie Chevrier –…READ MORE
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors…READ MORE
News about Neuroendocrine Cancer Expert Physicians
Three appointments and a newly established one-year neuroendocrine tumor (NET) fellowship herald an exciting new year for several NET specialists.
Edward M. Wolin, MD, Co-Medical Director of the Carcinoid Cancer Foundation, has been named Director…READ MORE